Risk Assessment on Use of *Lactobacillus rhamnosus* (LGG) as an Ingredient in Infant Formula and Baby Foods (II)

Espen Rimstad a*, Lene Frost Andersen b, Wenche Frølich c, Livar Frøyland d, Ernst Arne Høiby e, Georg Kapperud e, Margaretha Haugen e, Jørgen Lassen f, Bjørn-Tore Lunestad d, Helle Margrethe Meltzer e, Judith Narvhus a, Truls Nesbakken a, Karin Nygard e, Ørjan Olsvik g, Jan Erik Paulsen e, Lucy Robertson a, Michael Tranulis a, Morten Tryland a, Kirsti Vainio e and Ragnhild Halvorsen f

a Norwegian Scientific Committee for Food Safety (VKM), Norwegian University of Life Sciences (NMBU), Norway.
b Norwegian Scientific Committee for Food Safety (VKM), University of Oslo (UiO), Norway.
c Norwegian Scientific Committee for Food Safety (VKM), University of Stavanger (UiS), Norway.
d Norwegian Scientific Committee for Food Safety (VKM), Institute of Marine Research (NIFES), Norway.
e Norwegian Scientific Committee for Food Safety (VKM), Norwegian Institute of Public Health (FHI), Norway.
f Norwegian Scientific Committee for Food Safety (VKM), Norway.
g Norwegian Scientific Committee for Food Safety (VKM), The Arctic University of Norway (UiO), Norway.

Authors’ contributions

This work was carried out in collaboration among all authors. The opinion has been assessed and approved by the Panel on Food Additives, Flavourings, Processing Aids, Materials in Contact with Food and Cosmetics of the Norwegian Scientific Committee for Food Safety. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/EJNFS/2021/v13i130461

Received 02 October 2021
Accepted 05 December 2021
Published 27 December 2021

ABSTRACT

On 10. March 2006, The Norwegian Food Safety Authority (Mattilsynet) decided that, on the basis of VKM’s previous risk assessment (2005), Nutramigen 1 with *Lactobacillus rhamnosus* GG (LGG) could not be marketed in Norway as medical foods for infants (0-4 months). In addition, The
Norwegian Food Safety Authority (Mattilsynet) decided (08. November 2006) to withdraw permission for marketing of Nutramigen 2 with LGG, which is a milk supplement for infants aged between 4 and 6 months, with cow’s milk and soy protein allergy. On 13. December 2006, Mead Johnson Nutritionals appealed against this decision from The Norwegian Food Safety Authority (Mattilsynet). The Norwegian Food Safety Authority forwarded the appeal from the companies, asked the VKM Panel on biological hazards and the VKM Panel on nutrition, dietetic products, novel food and allergy, for a new risk assessment including the new data provided in the appeal.

LGG is one of the most studied probiotic strains. Lactic acid produced by LGG in the human gut results in a decrease in faecal pH, which in turn inhibits colonisation by potentially pathogenic bacteria. Short-term beneficial effects from administration of LGG to infants and young children with infectious diarrhoea have been reported in a number of studies, but a prophylactic effect on diarrhoea has not been documented. Furthermore, whilst some studies have reported a prophylactic, or even a curative, effect of LGG on atopic eczema in young children, more recent studies do not report such effects. Some even suggest an increased incidence of allergic sensitization in children receiving LGG supplemented formula at an early age. There are no published data that demonstrate long-term clinical benefits of infant formula supplemented with LGG for children between 4 months and 3 years, although no immediate deleterious effects of LGG have been found. Possible long-term effects of LGG on intestinal colonisation, and its effects on long-term gastrointestinal and immune functions, are not known.

LGG, as an ingredient in infant formula and baby foods, is intended for daily use in the target group, and not for short-term, specific treatment. Furthermore, the targeted consumer group includes children below the age of twelve months. These two aspects demand particular consideration with regard to the unknown effects of long-term treatment with large doses of live bacteria on the ecology of the microbiota of the gastrointestinal tract and on the immune system. Neither of these systems is fully matured in infants and small children, and therefore may be particularly susceptible.

There is no documented prophylactic effect of LGG on any disease in children. The effect of treatment with LGG-supplemented formula in small children is questionable, except for a documented short-term effect on infectious diarrhoea. Panel on Biological Hazards and Panel on nutrition, dietetic products, novel food and allergy at the Norwegian Scientific Committee for Food Safety find that the data available are not sufficient to support the suggested beneficial effects, or the safety, of LGG in infant formula and baby foods for children aged between 4 months and 3 years, when the products are intended for daily use.

**Keywords:** VKM; assessment; Norwegian Scientific Committee for Food Safety; baby foods.

**Available:** https://vkm.no/download/18.13735ab315cffecebb51fb56/1501077416972/63bb45d3eb.pdf

**NOTE:**

This work was carried out in collaboration between all authors. The opinion has been assessed and approved by the Panel on Biological Hazards and the Panel on Nutrition, Dietetic products, Novel foods and Allergy of VKM. All authors read and approved the final manuscript.

**Competence of VKM experts:** Persons working for VKM, either as appointed members of the Committee or as external experts, do this by virtue of their scientific expertise, not as representatives for their employers or third party interests. The Civil Services Act instructions on legal competence apply for all work prepared by VKM.

**COMPETING INTERESTS**

Authors have declared that no competing interests exist.

© 2021 Rimstad et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.